Abstract
Alteration of methylation status has been recognized as a possible epigenetic mechanism of selection during tumorigenesis in pancreatic cancer. This type of cancer is characterized by poor prognosis partly due to resistance to conventional drug treatments. We have used microarray technology to investigate the changes in global gene expression observed after treatment of different pancreatic cancer cell lines with the methylase inhibitor 5-aza-2′-deoxycytidine (5-aza-CdR). We have observed that this agent is able to inhibit to various degrees the growth of three pancreatic cancer cell lines. In particular, this inhibition was associated with induction of interferon (IFN)-related genes, as observed in other tumour types. Thus, expression of STAT1 seems to play a key role in the cellular response to treatment with the cytosine analogue. Moreover, we found increased p21WAF1 and gadd45A expression to be associated with the efficacy of the treatment; this induction may correlate with activation of the IFN signalling pathway. Expression of the p16INK protein was also linked to the ability of cells to respond to 5-aza-CdR. Finally, genome-wide demethylation induced sensitization that significantly increased response to further treatment with various chemotherapy agents.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- 5-aza-CdR:
-
5-aza-2′-deoxycytidine
- DNA MTase:
-
DNA methyltransferase
- IFN:
-
interferon
References
Adorjan P, Distler J, Lipscher E, Model F, Muller J, Pelet C, Braun A, Florl AR, Gutig D, Grabs G, Howe A, Kursar M, Lesche R, Leu E, Lewin A, Maier S, Muller V, Otto T, Scholz C, Schulz WA, Seifert HH, Schwope I, Ziebarth H, Berlin K, Piepenbrock C and Olek A . (2002). Nucleic Acids Res., 30, e21.
Al-Shahrour F, Diaz-Uriarte R and Dopazo J . (2004). Bioinformatics, 20, 578–580.
Ando T, Kawabe T, Ohara H, Ducommun B, Itoh M and Okamoto T . (2001). J. Biol. Chem., 276, 42971–42977.
Antequera F and Bird A . (1993). Proc. Natl. Acad. Sci. USA, 90, 11995–11999.
Antequera F, Boyes J and Bird A . (1990). Cell, 62, 503–514.
Aparicio A and Weber JS . (2002). Curr. Opin. Investig. Drugs, 3, 627–633.
Baylin SB, Herman JG, Graff JR, Vertino PM and Issa JP . (1998). Adv. Cancer Res., 72, 141–196.
Baylin SB, Makos M, Wu JJ, Yen RW, de Bustros A, Vertino P and Nelkin BD . (1991). Cancer Cells, 3, 383–390.
Beaulieu N, Morin S, Chute IC, Robert MF, Nguyen H and MacLeod AR . (2002). J. Biol. Chem., 277, 28176–28181.
Bender CM, Pao MM and Jones PA . (1998). Cancer Res., 58, 95–101.
Bird A, Taggart M, Frommer M, Miller OJ and Macleod D . (1985). Cell, 40, 91–99.
Bird AP . (1993). Cold Spring Harb. Symp. Quant. Biol., 58, 281–285.
Bromberg JF, Horvath CM, Wen Z, Schreiber RD and Darnell Jr JE . (1996). Proc. Natl. Acad. Sci. USA, 93, 7673–7678.
Brysk MM, Selvanayagam P, Arany I, Brysk H, Tyring SK and Rajaraman S . (1995). J. Interferon Cytokine Res., 15, 1029–1035.
Caraglia M, Pinto A, Correale P, Zagonel V, Genua G, Leardi A, Pepe S, Bianco AR and Tagliaferri P . (1994). Ann. Oncol., 5, 269–276.
Carrier F, Smith ML, Bae I, Kilpatrick KE, Lansing TJ, Chen CY, Engelstein M, Friend SH, Henner WD and Gilmer TM . (1994). J. Biol. Chem., 269, 32672–32677.
Chen B, He L, Savell VH, Jenkins JJ and Parham DM . (2000). Cancer Res., 60, 3290–3298.
Chin YE, Kitagawa M, Su WC, You ZH, Iwamoto Y and Fu XY . (1996). Science, 272, 719–722.
Chuang LS, Ian HI, Koh TW, Ng HH, Xu G and Li BF . (1997). Science, 277, 1996–2000.
Clemens MJ and McNurlan MA . (1985). Biochem. J., 226, 345–360.
Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC, Schuller DE, Yu L, Bloomfield CD, Caligiuri MA, Yates A, Nishikawa R, Su Huang H, Petrelli NJ, Zhang X, O'Dorisio MS, Held WA, Cavenee WK and Plass C . (2000). Nat. Genet., 24, 132–138.
Creusot F, Acs G and Christman JK . (1982). J. Biol. Chem., 257, 2041–2048.
Cross SH and Bird AP . (1995). Curr. Opin. Genet. Dev., 5, 309–314.
Davidson S, Crowther P, Radley J and Woodcock D . (1992). Eur. J. Cancer, 28, 362–368.
De Smet C, Lurquin C, Lethe B, Martelange V and Boon T . (1999). Mol. Cell. Biol., 19, 7327–7335.
Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC and Conklin BR . (2003). Genome Biol., 4, R7.
Dore BT and Momparler RL . (1992). Anticancer Drugs, 3, 281–287.
Dulic V, Stein GH, Far DF and Reed SI . (1998). Mol. Cell. Biol., 18, 546–557.
Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ikegaki N and Brodeur GM . (2000). Med. Pediatr. Oncol., 35, 603–607.
Fang JY and Lu YY . (2002). World J. Gastroenterol., 8, 400–405.
Ferguson AT, Evron E, Umbricht CB, Pandita TK, Chan TA, Hermeking H, Marks JR, Lambers AR, Futreal PA, Stampfer MR and Sukumar S . (2000). Proc. Natl. Acad. Sci. USA, 97, 6049–6054.
Furukawa T, Sunamura M, Motoi F, Matsuno S and Horii A . (2003). Am. J. Pathol., 162, 1807–1815.
Herman JG, Jen J, Merlo A and Baylin SB . (1996). Cancer Res., 56, 722–727.
Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, Samid D, Duan DS, Gnarra JR, Linehan WM and Baylin SB . (1994). Proc. Natl. Acad. Sci. USA, 91, 9700–9704.
Herman JG, Merlo A, Mao L, Lapidus RG, Issa JP, Davidson NE, Sidransky D and Baylin SB . (1995). Cancer Res., 55, 4525–4530.
Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, Furuichi K and Sakai T . (2003). Oncogene, 22, 7762–7773.
Hobeika AC, Etienne W, Cruz PE, Subramaniam PS and Johnson HM . (1998). Int. J. Cancer, 77, 138–145.
Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO and Goggins M . (2003). Am. J. Pathol., 162, 1151–1162.
Ihaka R and Gentleman R . (1996). J. Comput. Graphical Statist., 5, 299–314.
Jackson-Grusby L, Beard C, Possemato R, Tudor M, Fambrough D, Csankovszki G, Dausman J, Lee P, Wilson C, Lander E and Jaenisch R . (2001). Nat. Genet., 27, 31–39.
Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X, Mazzacurati L, Li X, Petrik KL, Rajasekaran B, Wu M and Zhan Q . (2002). Oncogene, 21, 8696–8704.
Jones ME . (1980). Annu. Rev. Biochem., 49, 253–279.
Jones PA and Buckley JD . (1990). Adv. Cancer Res., 54, 1–23.
Jones PL and Wolffe AP . (1999). Semin. Cancer Biol., 9, 339–347.
Kane MF, Loda M, Gaida GM, Lipman J, Mishra R, Goldman H, Jessup JM and Kolodner R . (1997). Cancer Res., 57, 808–811.
Karpf AR, Moore BC, Ririe TO and Jones DA . (2001). Mol. Pharmacol., 59, 751–757.
Karpf AR, Peterson PW, Rawlins JT, Dalley BK, Yang Q, Albertsen H and Jones DA . (1999). Proc. Natl. Acad. Sci. USA, 96, 14007–14012.
Kominsky S, Johnson HM, Bryan G, Tanabe T, Hobeika AC, Subramaniam PS and Torres B . (1998). Oncogene, 17, 2973–2979.
Kulaeva OI, Draghici S, Tang L, Kraniak JM, Land SJ and Tainsky MA . (2003). Oncogene, 22, 4118–4127.
Leonhardt H, Page AW, Weier HU and Bestor TH . (1992). Cell, 71, 865–873.
Liang G, Gonzales FA, Jones PA, Orntoft TF and Thykjaer T . (2002). Cancer Res., 62, 961–966.
Lu X, Tan CK, Zhou JQ, You M, Carastro LM, Downey KM and So AG . (2002). J. Biol. Chem., 277, 24340–24345.
Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D and Simon B . (2001). Cancer Res., 61, 5905–5910.
Michalowsky LA and Jones PA . (1987). Mol. Cell. Biol., 7, 3076–3083.
Moore PS, Sipos B, Orlandini S, Sorio C, Real FX, Lemoine NR, Gress T, Bassi C, Kloppel G, Kalthoff H, Ungefroren H, Lohr M and Scarpa A . (2001). Virchows Arch., 439, 798–802.
Nieto M, Samper E, Fraga MF, Gonzalez de Buitrago G, Esteller M and Serrano M . (2004). Oncogene, 23, 735–743.
Ottaviano YL, Issa JP, Parl FF, Smith HS, Baylin SB and Davidson NE . (1994). Cancer Res., 54, 2552–2555.
Paulin R, Grigg GW, Davey MW and Piper AA . (1998). Nucleic Acids Res., 26, 5009–5010.
Pisani P, Parkin DM, Bray F and Ferlay J . (1999). Int. J. Cancer, 83, 18–29.
Ramana CV, Chatterjee-Kishore M, Nguyen H and Stark GR . (2000). Oncogene, 19, 2619–2627.
Reid TR, Merigan TC and Basham TY . (1992). J. Interferon Res., 12, 131–137.
Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB and Vogelstein B . (2002). Nature, 416, 552–556.
Rideout III WM, Eversole-Cire P, Spruck III CH, Hustad CM, Coetzee GA, Gonzales FA and Jones PA . (1994). Mol. Cell. Biol., 14, 6143–6152.
Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M and Jones PA . (2000). Nucleic Acids Res., 28, 2108–2113.
Robertson KD, Uzvolgyi E, Liang G, Talmadge C, Sumegi J, Gonzales FA and Jones PA . (1999). Nucleic Acids Res., 27, 2291–2298.
Rousseau D, Cannella D, Boulaire J, Fitzgerald P, Fotedar A and Fotedar R . (1999). Oncogene, 18, 4313–4325.
Saito Y, Kanai Y, Sakamoto M, Saito H, Ishii H and Hirohashi S . (2002). Proc. Natl. Acad. Sci. USA, 99, 10060–10065.
Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM and Dryja TP . (1991). Am. J. Hum. Genet., 48, 880–888.
Santi DV, Norment A and Garrett CE . (1984). Proc. Natl. Acad. Sci. USA, 81, 6993–6997.
Santini V, Kantarjian HM and Issa JP . (2001). Ann. Intern. Med., 134, 573–586.
Sato N, Fukushima N, Maitra A, Iacobuzio-Donahue CA, van Heek NT, Cameron JL, Yeo CJ, Hruban RH and Goggins M . (2004). Am. J. Pathol., 164, 903–914.
Sato N, Fukushima N, Maitra A, Matsubayashi H, Yeo CJ, Cameron JL, Hruban RH and Goggins M . (2003a). Cancer Res., 63, 3735–3742.
Sato N, Maehara N, Su GH and Goggins M . (2003b). J. Natl. Cancer Inst., 95, 327–330.
Sato N, Maitra A, Fukushima N, van Heek NT, Matsubayashi H, Iacobuzio-Donahue CA, Rosty C and Goggins M . (2003c). Cancer Res., 63, 4158–4166.
Shuai K, Stark GR, Kerr IM and Darnell Jr JE . (1993). Science, 261, 1744–1746.
Sibinga NE, Wang H, Perrella MA, Endege WO, Patterson C, Yoshizumi M, Haber E and Lee ME . (1999). J. Biol. Chem., 274, 12139–12146.
Suh SI, Pyun HY, Cho JW, Baek WK, Park JB, Kwon T, Park JW, Suh MH and Carson DA . (2000). Cancer Lett., 160, 81–88.
Tazi J and Bird A . (1990). Cell, 60, 909–920.
Tiefenbrun N, Melamed D, Levy N, Resnitzky D, Hoffman I, Reed SI and Kimchi A . (1996). Mol. Cell. Biol., 16, 3934–3944.
Tusher VG, Tibshirani R and Chu G . (2001). Proc. Natl. Acad. Sci. USA, 98, 5116–5121.
Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, Issa JP, Hruban RH and Goggins M . (2001). Cancer Res., 61, 8540–8546.
Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH and Goggins M . (2000). Cancer Res., 60, 1835–1839.
Venkatasubbarao K, Ammanamanchi S, Brattain MG, Mimari D and Freeman JW . (2001). Cancer Res., 61, 6239–6247.
Weisenberger DJ, Velicescu M, Cheng JC, Gonzales FA, Liang G, Jones PA, Xu GL, Hu YG, Marquez VE, Nguyen CT, Lin JC, Preciado-Lopez MA and Tsai YC . (2004). Mol. Cancer Res., 2, 62–72.
Yamada T, Ohwada S, Saitoh F, Adachi M, Morishita Y and Hozumi M . (1996). Anticancer Res., 16, 735–740.
Yang YH, Dudoit S, Luu P, Lin DM, Peng V, Ngai J and Speed TP . (2002). Nucleic Acids Res., 30, e15.
Yoder JA and Bestor TH . (1996). Biol. Chem., 377, 605–610.
Youssef EM, Chen XQ, Higuchi E, Kondo Y, Garcia-Manero G, Lotan R and Issa JP . (2004). Cancer Res., 64, 2411–2417.
Zhu WG, Hileman T, Ke Y, Wang P, Lu S, Duan W, Dai Z, Tong T, Villalona-Calero MA, Plass C and Otterson GA . (2004). J. Biol. Chem., 279, 15161–15166.
Acknowledgements
This study was supported by grants from Cancer Research UK, National Translational Cancer Research Network (UK Department of Health), Associazione Italiana Ricerca Cancro (AIRC), Milan, Italy, Fondazione Giorgio Zanotto, Verona, Italy and Ministero Italiano Università e Ricerca, Rome, Italy.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc).
Rights and permissions
About this article
Cite this article
Missiaglia, E., Donadelli, M., Palmieri, M. et al. Growth delay of human pancreatic cancer cells by methylase inhibitor 5-aza-2′-deoxycytidine treatment is associated with activation of the interferon signalling pathway. Oncogene 24, 199–211 (2005). https://doi.org/10.1038/sj.onc.1208018
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208018
Keywords
This article is cited by
-
Dual EZH2 and G9a inhibition suppresses multiple myeloma cell proliferation by regulating the interferon signal and IRF4-MYC axis
Cell Death Discovery (2021)
-
Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells
Cell Death & Disease (2018)
-
Gemcitabine/Cisplatin Treatment Induces Concomitant SERTAD1, CDKN2B and GADD45A Modulation and Cellular Changes in Bladder Cancer Cells Regardless of the Site of TP53 Mutation
Pathology & Oncology Research (2018)
-
Pancreatic cancer heterogeneity and response to Mek inhibition
Oncogene (2017)
-
Methylation Status of the RIZ1 Gene Promoter in Human Glioma Tissues and Cell Lines
Cellular and Molecular Neurobiology (2017)